Potential Anti-Depressive Treatment Maneuvers from Bench to Bedside

  • Min Cai
  • Huaning WangEmail author
  • Xia ZhangEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1180)


Numerous antidepressants are available for the treatment of the major depressive disorder (MDD). Unfortunately, the disadvantages of these antidepressive medications, including inadequate treatment response, the therapeutic lag between drug administration and the onset of symptoms alleviation, and the safety consideration limit their clinical use and accelerate the exploration of advanced antidepressants with novel action mechanisms/newer targets, with fewer side effects. In this chapter, a series of compounds showing clinical potent in the treatment of MDD has been reviewed based on their reported results from different phase clinical trials. Although the majority of these strategies currently only lead to a systematic approach in the aspects of treatment resistant depression, some of them would be a routine clinical practice which is usable in the treatment of MDD, such as ketamine. Additionally, beyond the mechanism of action for novel therapeutic molecules involving glutamatergic, opiate, cholinergic receptors, and neuroplasticity, some supplemental procedures such as polyunsaturated fatty acids were also included in this chapter due to their solid property against MDD.


Novel pharmacological antidepressants Ketamine Neurotransmitters Anti-inflammation 


  1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72(7):537–547PubMedPubMedCentralCrossRefGoogle Scholar
  2. Aaronson ST, Sears P, Ruvuna F et al (2017) A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry 174(7):640–648PubMedCrossRefGoogle Scholar
  3. Aizawa E, Tsuji H, Asahara T et al (2016) Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder. J Affect Disord 202:254–257PubMedCrossRefGoogle Scholar
  4. Alasfar F, Ben-Nakhi M, Khoursheed M, Kehinde EO, Alsaleh M (2011) Selenium is significantly depleted among morbidly obese female patients seeking bariatric surgery. Obes Surg 21(11):1710–1713PubMedCrossRefGoogle Scholar
  5. Amsterdam JD, Kaplan M, Potter L, Bloom L, Rickels K (1986) Adinazolam, a new triazolobenzodiazepine, and imipramine in the treatment of major depressive disorder. Psychopharmacology 88(4):484–488PubMedCrossRefGoogle Scholar
  6. Barragan-Rodriguez L, Rodriguez-Moran M, Guerrero-Romero F (2008) Efficacy and safety of oral magnesium supplementation in the treatment of depression in the elderly with type 2 diabetes: a randomized, equivalent trial. Magnes Res 21(4):218–223Google Scholar
  7. Berman RM, Cappiello A, Anand A et al (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47(4):351–354PubMedCrossRefGoogle Scholar
  8. Bikson M, Grossman P, Thomas C et al (2016) Safety of transcranial direct current stimulation: evidence based update 2016. Brain Stimul 9(5):641–661Google Scholar
  9. Blier P, Zigman D, Blier J (2012) On the safety and benefits of repeated intravenous injections of ketamine for depression. Biol Psychiatry 72(4):e11–12PubMedCrossRefGoogle Scholar
  10. Blumberger DM, Vila-Rodriguez F, Thorpe KE et al (2018) Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. Lancet 391(10131):1683–1692PubMedCrossRefGoogle Scholar
  11. Brunoni AR, Moffa AH, Sampaio-Junior B et al (2017) Trial of electrical direct-current therapy versus escitalopram for depression. N Engl J Med 376(26):2523–2533PubMedCrossRefGoogle Scholar
  12. Carhart-Harris RL, Goodwin GM (2017) The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacology 42(11):2105–2113CrossRefGoogle Scholar
  13. Carhart-Harris RL, Bolstridge M, Rucker J et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 3(7):619–627CrossRefGoogle Scholar
  14. Chilukuri H, Reddy NP, Pathapati RM, Manu AN, Jollu S, Shaik AB (2014) Acute antidepressant effects of intramuscular versus intravenous ketamine. Indian J Psychol Med 36(1):71–76PubMedPubMedCentralCrossRefGoogle Scholar
  15. Dell’Osso B, Oldani L, Camuri G et al (2015) Augmentative repetitive transcranial magnetic stimulation (rTMS) in the acute treatment of poor responder depressed patients: a comparison study between high and low frequency stimulation. Eur Psychiatry: J Assoc Eur Psychiatrists 30(2):271–276CrossRefGoogle Scholar
  16. Diazgranados N, Ibrahim L, Brutsche NE et al (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67(8):793–802PubMedPubMedCentralCrossRefGoogle Scholar
  17. Donde C, Amad A, Nieto I et al (2017) Transcranial direct-current stimulation (tDCS) for bipolar depression: a systematic review and meta-analysis. Prog Neuro-Psychopharmacol Biol Psychiatry 78:123–131PubMedCrossRefGoogle Scholar
  18. Dos Santos RG, Balthazar FM, Bouso JC, Hallak JE (2016a) The current state of research on ayahuasca: a systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging. J Psychopharmacol 30(12):1230–1247PubMedCrossRefGoogle Scholar
  19. Dos Santos RG, Osorio FL, Crippa JA, Riba J, Zuardi AW, Hallak JE (2016b) Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. Ther Adv Psychopharmacol 6(3):193–213PubMedPubMedCentralCrossRefGoogle Scholar
  20. Drevets WC, Furey ML (2010) Replication of scopolamine’s antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial. Biol Psychiatry 67(5):432–438PubMedPubMedCentralCrossRefGoogle Scholar
  21. Emadi-Kouchak H, Mohammadinejad P, Asadollahi-Amin A et al (2016) Therapeutic effects of minocycline on mild-to-moderate depression in HIV patients: a double-blind, placebo-controlled, randomized trial. Int Clin Psychopharmacol 31(1):20–26PubMedCrossRefGoogle Scholar
  22. Fard FE, Mirghafourvand M, Mohammad-Alizadeh Charandabi S, Farshbaf-Khalili A, Javadzadeh Y, Asgharian H (2017) Effects of zinc and magnesium supplements on postpartum depression and anxiety: A randomized controlled clinical trial. Women Health 57(9):1115–1128CrossRefGoogle Scholar
  23. Fava M, McCall WV, Krystal A et al (2006) Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 59(11):1052–1060PubMedCrossRefGoogle Scholar
  24. Fond G, Hamdani N, Kapczinski F et al (2014) Effectiveness and tolerance of anti-inflammatory drugs’ add-on therapy in major mental disorders: a systematic qualitative review. Acta Psychiatr Scand 129(3):163–179PubMedCrossRefGoogle Scholar
  25. Furey ML, Drevets WC (2006) Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 63(10):1121–1129PubMedPubMedCentralCrossRefGoogle Scholar
  26. Griffiths RR, Johnson MW, Carducci MA et al (2016) Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J Psychopharmacol 30(12):1181–1197PubMedCrossRefGoogle Scholar
  27. Grober U, Schmidt J, Kisters K (2015) Magnesium in prevention and therapy. Nutrients 7(9):8199–8226PubMedPubMedCentralCrossRefGoogle Scholar
  28. Hallahan B, Ryan T, Hibbeln JR et al (2016) Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry: J Ment Sci 209(3):192–201CrossRefGoogle Scholar
  29. Hanusch KU, Janssen CH, Billheimer D et al (2013) Whole-body hyperthermia for the treatment of major depression: associations with thermoregulatory cooling. Am J Psychiatry 170(7):802–804PubMedCrossRefGoogle Scholar
  30. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC (2007) Reduced prefrontal glutamate/glutamine and gamma-aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 64(2):193–200PubMedCrossRefGoogle Scholar
  31. Heresco-Levy U, Gelfin G, Bloch B et al (2013) A randomized add-on trial of high-dose D-cycloserine for treatment-resistant depression. Int J Neuropsychopharmacol 16(3):501–506PubMedCrossRefGoogle Scholar
  32. Huang CC, Wei IH, Huang CL et al (2013) Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 74(10):734–741PubMedCrossRefGoogle Scholar
  33. Husain MI, Chaudhry IB, Rahman RR et al (2015) Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial. Trials 16:410Google Scholar
  34. Husain MI, Chaudhry IB, Hamirani MM et al (2017) Minocycline and celecoxib as adjunctive treatments for bipolar depression: a study protocol for a multicenter factorial design randomized controlled trial. Neuropsychiatr Dis Treat 13:1–8CrossRefGoogle Scholar
  35. Ibrahim L, Diazgranados N, Luckenbaugh DA et al (2011) Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression. Prog Neuro-Psychopharmacol Biol Psychiatry 35(4):1155–1159PubMedCrossRefPubMedCentralGoogle Scholar
  36. Ibrahim L, Diaz Granados N, Jolkovsky L et al (2012) A Randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder. J Clin Psychopharmacol 32(4):551–557PubMedPubMedCentralCrossRefGoogle Scholar
  37. Iglesias P, Selgas R, Romero S, Diez JJ (2013) Selenium and kidney disease. J Nephrol 26(2):266–272PubMedCrossRefPubMedCentralGoogle Scholar
  38. Jain FA, Hunter AM, Brooks JO 3rd, Leuchter AF (2013) Predictive socioeconomic and clinical profiles of antidepressant response and remission. Depress Anxiety 30(7):624–630PubMedCrossRefPubMedCentralGoogle Scholar
  39. Janssen CW, Lowry CA, Mehl MR et al (2016) Whole-body hyperthermia for the treatment of major depressive disorder: a randomized clinical trial. JAMA Psychiatry 73(8):789–795PubMedCrossRefGoogle Scholar
  40. Kantrowitz JT, Halberstam B, Gangwisch J (2015) Single-dose ketamine followed by daily D-Cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry 76(6):737–738Google Scholar
  41. Kellner CH, Husain MM, Knapp RG et al (2016a) A novel strategy for continuation ECT in geriatric depression: phase 2 of the PRIDE study. Am J Psychiatry 173(11):1110–1118PubMedCrossRefGoogle Scholar
  42. Kellner CH, Husain MM, Knapp RG et al (2016b) Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. Am J Psychiatry 173(11):1101–1109PubMedCrossRefGoogle Scholar
  43. Krystal JH, Madonick S, Perry E et al (2006) Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacology 31(8):1793–1800CrossRefGoogle Scholar
  44. Lai J, Moxey A, Nowak G, Vashum K, Bailey K, McEvoy M (2012) The efficacy of zinc supplementation in depression: systematic review of randomised controlled trials. J Affect Disord 136(1–2):e31–e39PubMedCrossRefGoogle Scholar
  45. Lapidus KA, Levitch CF, Perez AM et al (2014) A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 76(12):970–976PubMedPubMedCentralCrossRefGoogle Scholar
  46. Larkin GL, Beautrais AL (2011) A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. Int J Neuropsychopharmacol 14(8):1127–1131PubMedCrossRefGoogle Scholar
  47. Luscher B, Shen Q, Sahir N (2011) The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 16(4):383–406PubMedPubMedCentralCrossRefGoogle Scholar
  48. Marks DM, Abramowitz JS, Spielmans GI (2012) Concerns about data reporting and interpretation in “Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial”. J Psychiatr Res 46(5):692–693; author reply 694–695PubMedCrossRefGoogle Scholar
  49. Martins JG (2009) EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr 28(5):525–542PubMedCrossRefGoogle Scholar
  50. Meron D, Hedger N, Garner M, Baldwin DS (2015) Transcranial direct current stimulation (tDCS) in the treatment of depression: systematic review and meta-analysis of efficacy and tolerability. Neurosci Biobehav Rev 57:46–62PubMedCrossRefGoogle Scholar
  51. Mion G, Villevieille T (2013) Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci & Ther 19(6):370–380Google Scholar
  52. Miyaoka T, Wake R, Furuya M et al (2012) Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study. Prog Neuro-Psychopharmacol Biol Psychiatry 37(2):222–226PubMedCrossRefGoogle Scholar
  53. Mokhber N, Namjoo M, Tara F et al (2011) Effect of supplementation with selenium on postpartum depression: a randomized double-blind placebo-controlled trial. J Matern-Fetal Neonatal Med: Off J Eur Assoc Perinat Med, Fed Asia Ocean Perinat Soc, Int Soc Perinat Obstet 24(1):104–108CrossRefGoogle Scholar
  54. Mrazek DA, Hornberger JC, Altar CA, Degtiar I (2014) A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatric Serv 65(8):977–987PubMedCrossRefGoogle Scholar
  55. Mullard A (2016) Deuterated drugs draw heavier backing. Nat Rev Drug Discov 15(4):219–221PubMedCrossRefGoogle Scholar
  56. Murrough JW, Perez AM, Pillemer S et al (2013) Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 74(4):250–256PubMedCrossRefGoogle Scholar
  57. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH (2006) Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry 163(6):1098–1100PubMedCrossRefGoogle Scholar
  58. Nitsche MA, Paulus W (2000) Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol 527 Pt 3:633–639PubMedPubMedCentralCrossRefGoogle Scholar
  59. Osorio Fde L, Sanches RF, Macedo LR et al (2015) Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. Revista brasileira de psiquiatria 37(1):13–20CrossRefGoogle Scholar
  60. Petty F, Trivedi MH, Fulton M, Rush AJ (1995) Benzodiazepines as antidepressants: does GABA play a role in depression? Biol Psychiatry 38(9):578–591PubMedCrossRefGoogle Scholar
  61. Practice guideline for the treatment of patients with major depressive disorder (revision) (2000) American Psychiatric Association. Am J Psychiatry 157(4 Suppl):1–45Google Scholar
  62. Preskorn S, Macaluso M, Mehra DO et al (2015) Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 21(2):140–149PubMedCrossRefGoogle Scholar
  63. Raison CL, Hale MW, Williams LE, Wager TD, Lowry CA (2014) Somatic influences on subjective well-being and affective disorders: the convergence of thermosensory and central serotonergic systems. Front Psychol 5:1580Google Scholar
  64. Rasmussen KG, Lineberry TW, Galardy CW et al (2013) Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 27(5):444–450PubMedCrossRefGoogle Scholar
  65. Rayman M, Thompson A, Warren-Perry M et al (2006) Impact of selenium on mood and quality of life: a randomized, controlled trial. Biol Psychiatry 59(2):147–154PubMedCrossRefGoogle Scholar
  66. Rice SM, Hickie IB, Yung AR et al (2016) Youth depression alleviation: the fish oil youth depression study (YoDA-F): a randomized, double-blind, placebo-controlled treatment trial. Early Interv Psychiatry 10(4):290–299PubMedCrossRefGoogle Scholar
  67. Rolls ET, Grabenhorst F, Parris BA (2008) Warm pleasant feelings in the brain. NeuroImage 41(4):1504–1513PubMedCrossRefGoogle Scholar
  68. Rush AJ, George MS, Sackeim HA et al (2000) Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry 47(4):276–286Google Scholar
  69. Rush AJ, Trivedi MH, Wisniewski SR et al (2006) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163(11):1905–1917CrossRefGoogle Scholar
  70. Salardini E, Zeinoddini A, Mohammadinejad P et al (2016) Riluzole combination therapy for moderate-to-severe major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatr Res 75:24–30PubMedCrossRefGoogle Scholar
  71. Sanacora G, Gueorguieva R, Epperson CN et al (2004) Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 61(7):705–713PubMedCrossRefGoogle Scholar
  72. Sawada T, Yokoi K (2010) Effect of zinc supplementation on mood states in young women: a pilot study. Eur J Clin Nutr 64(3):331–333PubMedCrossRefGoogle Scholar
  73. Segmiller F, Ruther T, Linhardt A et al (2013) Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 53(9):996–998Google Scholar
  74. Shiroma PR, Johns B, Kuskowski M et al (2014) Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. J Affect Disord 155:123–129PubMedCrossRefGoogle Scholar
  75. Short B, Fong J, Galvez V, Shelker W, Loo CK (2018) Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry 5(1):65–78PubMedCrossRefGoogle Scholar
  76. Siwek M, Dudek D, Paul IA et al (2009) Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord 118(1–3):187–195PubMedCrossRefGoogle Scholar
  77. Steenbergen L, Sellaro R, van Hemert S, Bosch JA, Colzato LS (2015) A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood. Brain Behav Immun 48:258–264PubMedCrossRefGoogle Scholar
  78. Su KP, Lai HC, Yang HT et al (2014) Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry 76(7):559–566PubMedCrossRefPubMedCentralGoogle Scholar
  79. Szymkowicz SM, Finnegan N, Dale RM (2013) A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 147(1–3):416–420PubMedCrossRefGoogle Scholar
  80. Tarleton EK, Littenberg B, MacLean CD, Kennedy AG, Daley C (2017) Role of magnesium supplementation in the treatment of depression: a randomized clinical trial. PloS One 12(6):e0180067PubMedPubMedCentralCrossRefGoogle Scholar
  81. Tiligada E, Kyriakidis K, Chazot PL, Passani MB (2011) Histamine pharmacology and new CNS drug targets. CNS Neurosci Ther 17(6):620–628CrossRefGoogle Scholar
  82. Tran P, Skolnick P, Czobor P et al (2012) Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Psychiatric Res 46(1):64–71PubMedCrossRefGoogle Scholar
  83. Viereck V, Gamper M, Re: Kirchin V, Page T, Keegan PE, Atiemo KO, Cody JD, McClinton S, Aluko P (2017) Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 7:CD003881. Neurourol Urodyn 37(7):2286–2287
  84. Ward SE, Bax BD, Harries M (2010) Challenges for and current status of research into positive modulators of AMPA receptors. Br J Pharmacol1 60(2):181–190PubMedPubMedCentralCrossRefGoogle Scholar
  85. Williams NR, Heifets BD, Blasey C et al (2018) Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 175(12):1205–1215PubMedCrossRefGoogle Scholar
  86. Zarate CA Jr, Payne JL, Quiroz J et al (2004) An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry 161(1):171–174PubMedCrossRefGoogle Scholar
  87. Zarate CA Jr, Singh JB, Carlson PJ et al (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63(8):856–864PubMedPubMedCentralCrossRefGoogle Scholar
  88. Zarate CA Jr, Brutsche NE, Ibrahim L et al (2012) Replication of ketamine’s antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71(11):939–946PubMedPubMedCentralCrossRefGoogle Scholar
  89. Zhang XL, Sullivan JA, Moskal JR, Stanton PK (2008) A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus. Neuropharmacology 55(7):1238–1250PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Psychiatry, Xijing HospitalFourth Military Medical UniversityXi’anChina
  2. 2.Departments of Psychiatry and Cellular and Molecular MedicineUniversity of Ottawa, Institute of Mental Health Research at the RoyalOttawaCanada

Personalised recommendations